Cambridge-based biotechnology company 4basebio PLC (AIM: 4BB) announced on Monday that it has launched a high-capacity single-stranded DNA (ssDNA) platform designed to support the development of next-generation genetic therapies, including CRISPR-based gene editing, cell engineering and nucleic acid medicines.

This platform uses a proprietary enzymatic manufacturing process to produce high-purity, long-form ssDNA templates with protected ends, addressing manufacturing and performance limitations associated with traditional chemical synthesis. The company said the technology enables production of constructs up to 10,000 nucleotides while improving stability, reducing immunogenicity and supporting clinical-scale manufacturing.

According to 4basebio, demand for longer and safer DNA templates has increased alongside growth in complex gene-editing applications, particularly "knock-in" therapies. The company expects the platform to accelerate the development of clinically viable therapeutics.

The technology will be presented at the upcoming American Society of Gene & Cell Therapy annual meeting in Boston, where Amine Bouchareb, Director of Molecular Biology and Gene Editing at 4basebio, will deliver a presentation on 14 May titled "An enzymatic ssDNA platform addresses manufacturing and performance bottlenecks in non-viral CRISPR gene editing".

4basebio develops synthetic DNA and mRNA products for gene therapies, genome editing, DNA vaccines and mRNA production through its proprietary enzymatic DNA synthesis platform.